Mannatech, Inc. — FY2011 Form 10-K
Reporting period: Fiscal year ended December 31, 2011; comparisons are primarily with FY2010. The filing also presents unaudited quarterly results. Unless noted otherwise, financial amounts below are in U.S. dollars.
Business context
Mannatech develops and sells nutritional supplements, skin-care and weight-management products through independent associates and members in 21 countries. It reports as one operating segment. Approximately 372,000 associates and members purchased products during the year, down from 403,000 in 2010. The company relies on third-party manufacturers and its network-marketing distribution model.
Financial results and liquidity
| Metric | FY2011 | FY2010 | Change |
|---|---|---|---|
| Net sales | $200.7 million | $228.1 million | Down 12.0% |
| Gross profit / margin | $82.8 million / 41.3% | $98.0 million / 43.0% | Margin down 1.7 percentage points |
| Operating loss | $16.9 million | $11.5 million | Loss increased |
| Net loss | $20.7 million | $10.6 million | Loss increased |
| Basic and diluted loss per share | $7.80 | $4.01 | Loss per share increased |
| Cash from operating activities | $(2.9) million | $4.0 million | Cash generation weakened |
| Capital expenditures | $1.6 million | $3.8 million | Down |
Sales fell in both the United States (down 16.7%) and international markets (down 8.3%); favorable currency translation added approximately $7.2 million to reported sales. Product sales declined 8.4% and pack sales declined 31.9%. Orders fell 13%, while average order value rose 5.6%. Commissions and incentives totaled $87.4 million, or 43.6% of sales, compared with 42.7% in 2010.
Cash and cash equivalents were $18.1 million at year-end, down from $21.6 million. Working capital was $11.9 million, down from $23.0 million. Total assets were $58.3 million and shareholders’ equity was $21.7 million. Management described the company as virtually debt-free; the balance sheet reported $2.2 million of capital-lease obligations ($0.9 million current and $1.4 million long-term). Dividends remained suspended.
For the fourth quarter, net sales were $47.9 million versus $54.9 million a year earlier; gross profit was $18.8 million versus $24.2 million; and net loss was $6.9 million versus $2.7 million. Quarterly loss per share was $2.63 versus $1.04, adjusted for the subsequent 1-for-10 reverse stock split.
Material changes and notable items
- Core Ambrotose products generated $82.4 million, or 41.0% of FY2011 sales, up from 35.3% of sales in 2010. Advanced Ambrotose sales rose to $66.9 million, while Ambrotose sales fell to $15.5 million.
- Cost of sales rose to 15.2% of sales from 14.4%, partly due to higher inventory write-off reserves. Selling and administrative expense declined in dollars but was 27.8% of sales versus 27.5%.
- A U.S. restructuring eliminated 98 positions; management reported $7.2 million of operating-cost reductions in the second half of 2011 versus the comparable 2010 period. Employees totaled 387 at year-end, compared with 490.
- Depreciation and amortization was $10.7 million. Management attributed $5.7 million of depreciation to the ERP system and expected its remaining book value to be fully depreciated by the second quarter of 2012.
- Inventory reserves increased to $2.3 million from $1.6 million. The valuation allowance against deferred tax assets increased to $9.5 million from $4.1 million.
Outlook, risks and contingencies
Management’s 2012 priorities were restoring sales volume and profitability and generating positive operating cash flow. Plans included a new product launch, a worldwide recruitment and sales system, further development of recently opened markets, and continued expense reductions. Management expected operating cash flows to fund current operations, but cautioned that this was not assured. It stated that existing liquidity and anticipated cash flows should cover normal operations and possible expansion for 12–24 months.
- Tax dispute: The IRS proposed an $8.5 million tax deficiency plus $1.5 million of penalties for 2005–2009. Mannatech contested the proposed adjustments and was pursuing IRS Appeals. The company reported $4.0 million of uncertain-tax-position liabilities and ongoing tax audits.
- Litigation and settlements: In March 2012, Mannatech agreed to pay Marinova $2.6 million and forgive a $618,750 amount owed; the settlement was recorded in FY2011. A product-liability suit was also settled in March 2012; the settlement amount is not stated in the filing text. The company reported $3.1 million accrued for litigation matters at year-end.
- Business and regulatory exposure: Results depend on recruiting and retaining associates, product demand, and the network-marketing model. The filing highlights regulatory scrutiny of product and income claims, possible associate misconduct, intense competition, adverse publicity, and the risk of product-liability claims.
- Concentration and supply: Ambrotose-related products accounted for 41.0% of sales. The company identified Arabinogalactan, an Ambrotose ingredient, as lacking an alternative supplier at the time of filing.
- Currency and listing: 58.2% of FY2011 sales came from outside the United States; the company did not hedge foreign-currency exposure. After a Nasdaq minimum-bid-price deficiency, a 1-for-10 reverse split took effect in January 2012 and Nasdaq confirmed regained compliance on January 31, 2012; continued compliance was not assured.
- Funding and obligations: The company had access, subject to conditions, to a $10 million equity line with Dutchess; no shares had been issued under it as of March 29, 2012. Drawdowns could dilute shareholders. Contractual commitments totaled $24.7 million, including leases, purchase obligations, royalties and employment agreements.
The independent auditor issued an unqualified opinion on the consolidated financial statements. Management concluded that disclosure controls and internal control over financial reporting were effective as of December 31, 2011.
Important facts for investors to verify
- Whether sales, associate recruitment and order activity stabilized after the continued FY2011 declines.
- Whether cost reductions and the ERP depreciation roll-off translated into sustained positive operating cash flow and improved profitability.
- The resolution and cash impact of the IRS proposed adjustments, other tax audits, and the litigation settlements.
- Whether Ambrotose concentration and dependence on key ingredients or suppliers create continuing earnings or supply risk.
- Current liquidity, capital-lease and purchase commitments, and whether the Dutchess equity line was accessed after the filing date.
- Ongoing Nasdaq listing compliance and the effect of the reverse split on share price, liquidity and potential dilution.